Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000950170-24-019045

Chief R&D Officer sold 9,014 shares at $0.68 ($6,130)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Zalevsky Jonathan Chief R&D Officer 2024-02-20 Sale −9,014 $0.68 $6,130 265,025 D
Open-market sales · 9,014 sh · avg $0.68 · $6,130
Loading xslF345X05/ownership.xml…